Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy October 24, 2026 1:00 PM EDTCompany ...
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...
Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/Getty. A ...
The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...
Because they can be developed rapidly, mRNA vaccines have the potential to bring personalized care, while others can be ...
When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...
A first-of-its-kind vaccine against cancer may be on the horizon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results